A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept
NCT ID: NCT01339481
Last Updated: 2011-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
26 participants
OBSERVATIONAL
2011-02-28
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects with RA initiating abatacept treatment regimen
Subjects naïve to both abatacept and belatacept
abatacept
Intravenous Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
abatacept
Intravenous Infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is willing and able to comply with study visits and procedures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Perseid Therapeutics LLC
UNKNOWN
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Astellas Pharma Global Development
Principal Investigator
Role: PRINCIPAL_INVESTIGATOR
Metroplex Clinical Research Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pinnacle Research Group, LLC
Anniston, Alabama, United States
Arthritis Research of Florida
Palm Harbor, Florida, United States
The Center for Rheumatology and Bone Research
Wheaton, Maryland, United States
North Shore - Long Island Jewish Health System
Lake Success, New York, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Low County Rheumatology
North Charleston, South Carolina, United States
Metroplex Clinical Research Center
Dallas, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2408-CL-0103
Identifier Type: -
Identifier Source: org_study_id